Figure 2
Figure 2. SET and SETBP1 at diagnosis and follow-up. SET protein is low at diagnosis in patients who subsequently progress to BC. (A) mRNA expression of SETBP1. No significant differences in SETBP1 expression were observed between the 3 response groups. CCR, n = 14; No-CCR, n = 11; and BC, n = 6. (B) Levels of SET protein. SET protein levels are higher than in normal MNCs (mean level in 10 healthy subjects = 0.2; range, 0.1-0.3) in the CCR and No-CCR groups (P < .001 and P = .01, respectively). CCR, n = 14; No-CCR, n = 11; and BC, n = 6. (C) SET mRNA expression. CCR, n = 14; No-CCR, n = 11; and BC, n = 6. (D) Level of SET protein in CD34+ cells. The level of SET protein assessed at diagnosis does not correlate with the patients' eventual clinical outcome, although this outcome is based on only 3 patients who later progressed while on imatinib treatment. CCR, n = 3; No-CCR, n = 4; and BC, n = 3.

SET and SETBP1 at diagnosis and follow-up. SET protein is low at diagnosis in patients who subsequently progress to BC. (A) mRNA expression of SETBP1. No significant differences in SETBP1 expression were observed between the 3 response groups. CCR, n = 14; No-CCR, n = 11; and BC, n = 6. (B) Levels of SET protein. SET protein levels are higher than in normal MNCs (mean level in 10 healthy subjects = 0.2; range, 0.1-0.3) in the CCR and No-CCR groups (P < .001 and P = .01, respectively). CCR, n = 14; No-CCR, n = 11; and BC, n = 6. (C) SET mRNA expression. CCR, n = 14; No-CCR, n = 11; and BC, n = 6. (D) Level of SET protein in CD34+ cells. The level of SET protein assessed at diagnosis does not correlate with the patients' eventual clinical outcome, although this outcome is based on only 3 patients who later progressed while on imatinib treatment. CCR, n = 3; No-CCR, n = 4; and BC, n = 3.

Close Modal

or Create an Account

Close Modal
Close Modal